Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

The supply of plasma for cryoprecipitate and for sending it to make concentrate at that stage was 300,000 donations a year.

Published on: 30 August, 2024

Dr John Wallace argued that the threshold required was that an adequate amount of a good quality cryoprecipitate would probably cover most clinical indications for Factor 8 therapy.

Published on: 30 August, 2024

In a meeting it was stressed that Dr Bigg's paper indicated in five years time there may be a need for more material, haemophilia centre directors and transfusion directors approved the contents of the paper and recommended that this document be used as the basis for planning the future requirements for Factor 8 in the United Kingdom.

Published on: 30 August, 2024

Dr Biggs argued that the problem pertained to large available stocks of therapeutic materials in stores because no-one would buy them whilst patients were simultaneously in dire need of this same material.

Published on: 30 August, 2024

In Lord David Owen's response to parliamentary questions he argued that concentrates were the optimum treatment and commercial product was available. However, UK domestic production should increase and home treatment was desirable.

Published on: 30 August, 2024

The main reason for the expansion in producing clotting factor concentrates at the time was to produce more immunoglobulin to prevent rubella in pregnancy, following an outbreak.

Published on: 30 August, 2024

Transfusion directors in the Joint Steering Committee on Blood Products Production increased the goal of 250,000 donations in March 1973 to 275,000 in June and July 1973.

Published on: 30 August, 2024

The goal of 275,000 donations for Factor 8 production had not been met a year after it had been given from 1973 to 1974.

Published on: 30 August, 2024

Dr Maycock argued for the principle of self-sufficiency and that unpaid donations must be preserved, blood transfusion services in the UK must be self-supporting and there should be agreed UK targets for the provision of preparations of human blood. The supply of plasma for fractionation needed to increase if the shortfall in meeting the anticipated demand was to be met from within the NHS.

Published on: 17 October, 2024

An article in The Lancet demonstrated the pressure put on the Government to act by clinicians, the medical press, NBTS and advisory bodies.

Published on: 30 August, 2024

Professor Blackburn wrote to Dr Waiter, which demonstrated the pressure put on the Government to act by clinicians, by the medical press, by NBTS and advisory bodies.

Published on: 30 August, 2024

A letter was written to Dr Waiter which demonstrated the pressure put on the Government to act by clinicians, the medical press, NBTS and advisory bodies.

Published on: 30 August, 2024

Dr Waiter wrote to Professor Blackburn, which demonstrated the pressure put on the Government to act by clinicians, the medical press, NBTS and advisory bodies.

Published on: 30 August, 2024

Lord David Owen stated that a major motivating factor for self-sufficiency, as far as he was concerned, was to ensure the safety of the patient. This included dangers of hepatitis, and the increased risks posed by the pool sizes used by commercial companies.

Published on: 30 August, 2024

A note of a meeting with the Minister of State (Health) outlined that the Haemophilia Society was anxious that the volume target set by the Department for self-sufficiency might not be sufficient in practice.

Published on: 30 August, 2024

A note from M Draper to Thomas Dutton noted that Dr Owen had asked to have a copy of the MRC report from which the Haemophilia Society were quoting and which had also mentioned Dr Rosemary Biggs.

Published on: 30 August, 2024

RTD (75) 26 set out regional transfusion directors' estimates of the number of donations to be used for the production of fresh plasma from AHG concentrate each quarter from 1975 to mid 1977.

Published on: 30 August, 2024

A memo from Thomas Dutton noted that a recent meeting of the Expert Group on the Treatment of Haemophilia advised that NHS Factor 8 production may have provided no more than about one third of the likely requirement for Factor 8 in a few years time.

Published on: 30 August, 2024

A note on anti-haemophilic globulin concentrate outlined that the target figure to which they were currently working was no longer sufficient to meet the probable treatment needs of people with haemophilia in a few years time, having been overtaken by the unexpected rapid introduction of home therapy.

Published on: 30 August, 2024

A letter from Gerry Grimstone to Thomas Dutton outlined Dr Owen's stance that the National Blood Transfusion Service needed to be reformed.

Published on: 30 August, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2124
  • Page 2125
  • Page 2126
  • Page 2127
  • Current page 2128
  • Page 2129
  • Page 2130
  • Page 2131
  • Page 2132
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.